Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXA2JO
|
||||
Drug Name |
[4-(2,4-Difluoro-5-methoxycarbamoyl-phenylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid 1-methyl-piperidin-4-yl ester
|
||||
Synonyms |
CHEMBL191594
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C24H29F2N7O4
|
||||
Canonical SMILES |
CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OC4CCN(C)CC4)c(C(C)C)c23)c(F)cc1F
|
||||
InChI |
InChI=1S/C24H29F2N7O4/c1-13(2)20-19(30-24(35)37-14-5-7-32(3)8-6-14)11-33-21(20)22(27-12-28-33)29-18-9-15(23(34)31-36-4)16(25)10-17(18)26/h9-14H,5-8H2,1-4H3,(H,30,35)(H,31,34)(H,27,28,29)
|
||||
InChIKey |
NZBQAOCZTUIYGZ-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
HIF-1 signaling pathway | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
S1P3 pathway | |||||
VEGFR1 specific signals | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.